Which has the lower trailing P/E, SYK or VRTX?

VRTX has the lower trailing P/E: SYK trades at 33.75 and VRTX at 28.30. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, SYK or VRTX?

Over the past five years, VRTX grew revenue faster — SYK at a 9.72% CAGR versus VRTX at 13.82%.

Does SYK or VRTX pay a bigger dividend?

SYK pays a dividend (1.07% yield), while VRTX has no payments in the available dividend history.

Is SYK or VRTX more profitable?

VRTX runs the higher net margin — SYK at 14.43% versus VRTX at 35.40%.

How have SYK and VRTX total returns compared?

Over the past 10 years, SYK delivered 12.07% and VRTX delivered 17.26% annualized total return. Past performance doesn't predict future results.

Stryker Corporation (SYK) vs Vertex Pharmaceuticals Incorporated (VRTX)

A side-by-side comparison of Stryker Corporation and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 31, 2026. Differences are shown without an overall score or investment verdict.

SYK

Stryker Corporation

$124.86B

$325.70HealthcareDelayed quote: Jul 31, 2026, 4:00 PM EDT

VRTX

Vertex Pharmaceuticals Incorporated

$121.09B

$477.10HealthcareDelayed quote: Jul 31, 2026, 4:00 PM EDT

Total return — SYK vs VRTX

growth of $100 · dividends reinvested · last 30y

SYK +6840.2%VRTX +3535.0%SYK compounded faster

SYK VRTX

SYK vs VRTX: by the numbers

•SYK is the larger company ($124.86B vs $121.09B market cap).
•VRTX trades at the lower trailing earnings multiple (28.30 vs 33.75 P/E), one valuation lens rather than an overall verdict.
•VRTX converts more revenue to profit (35.40% vs 14.43% net margin).
•VRTX grew revenue faster over the past five years (13.82% vs 9.72% CAGR).
•SYK pays a dividend (1.07% yield), while VRTX has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	SYK	VRTX
P/E ratio	33.75	28.30
Forward P/E	21.73	24.81
P/S ratio	4.87	9.98
P/B ratio	2.62	6.32
PEG ratio	5.16	3.46
EV / EBITDA	20.56	23.80
FCF yield	3.63%	3.03%

Profitability

Metric	SYK	VRTX
Gross margin	65.17%	86.28%
Operating margin	22.03%	38.97%
Net margin	14.43%	35.40%
ROE	7.78%	22.41%
ROIC	8.53%	18.12%

Dividends

Metric	SYK	VRTX
Dividend yield	1.07%	N/A
Payout ratio	40.99%	N/A

Growth (annualized)

Metric	SYK	VRTX
Revenue CAGR (5Y)	9.72%	13.82%
EPS CAGR (5Y)	14.79%	8.17%
FCF CAGR (5Y)	11.01%	4.01%
Total return CAGR (5Y)	4.83%	18.80%

Frequently asked

Which has the lower trailing P/E, SYK or VRTX?: VRTX has the lower trailing P/E: SYK trades at 33.75 and VRTX at 28.30. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, SYK or VRTX?: Over the past five years, VRTX grew revenue faster — SYK at a 9.72% CAGR versus VRTX at 13.82%.
Does SYK or VRTX pay a bigger dividend?: SYK pays a dividend (1.07% yield), while VRTX has no payments in the available dividend history.
Is SYK or VRTX more profitable?: VRTX runs the higher net margin — SYK at 14.43% versus VRTX at 35.40%.
How have SYK and VRTX total returns compared?: Over the past 10 years, SYK delivered 12.07% and VRTX delivered 17.26% annualized total return. Past performance doesn't predict future results.

Go deeper

Full SYK analysis Full VRTX analysis Interactive comparison tool

Dig into the metrics

Stryker P/E ratio Vertex Pharmaceuticals P/E ratio Stryker dividend yield Vertex Pharmaceuticals dividend yield Stryker ROE Vertex Pharmaceuticals ROE Stryker operating margin Vertex Pharmaceuticals operating margin Stryker revenue growth Vertex Pharmaceuticals revenue growth Stryker free cash flow Vertex Pharmaceuticals free cash flow

Stryker & Vertex Pharmaceuticals appear in these rankings

25+ Year Dividend Growers Highest ROIC Stocks Highest Operating Margin Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 31, 2026.